3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Liver Failure
1
Leukemia-Lymphoma, Adult T-Cell
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
Head and Neck Neoplasms
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
202
lenvatinib
129
Bevacizumab
124
Nivolumab
85
pembrolizumab
72
atezolizumab
72
Radiosurgery
71
durvalumab
63
Oxaliplatin
59
sintilimab
57
Fluorouracil
54
Doxorubicin
44
tislelizumab
43
apatinib
43
Leucovorin
40
tremelimumab
37
camrelizumab
37
Radiofrequency Ablation
37
Radiotherapy
36
Magnetic Resonance Spectroscopy
32
Capecitabine
30
regorafenib
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Hepatectomy
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
toripalimab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Hepatocellular
×
Raltegravir Potassium
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled